Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Friess

Showing results (701-710 of 770) with videos related to

Pageof 77
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2017
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment ResponseAlexander Muckenhuber, Anne Katrin Berger, Anna Melissa Schlitter, et al.
Journal of Cellular and Molecular Medicine|February 27, 2008
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profilingChristian Pilarsky, Ole Ammerpohl, Bence Sipos, et al.
Gastroenterology|January 3, 2021
mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote Kras<sup>G12D</sup>-Induced Acinar-to-Ductal Metaplasia and Early Pancreatic CarcinogenesisYamin Zhao, Benjamin Schoeps, Dianbo Yao, et al.
The Lancet. Gastroenterology & Hepatology|December 18, 2020
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trialVolker Kunzmann, Jens T Siveke, Hana Algül, et al.
EJNMMI Research|July 29, 2021
[<sup>18</sup>F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinomaFelix N Harder, Friederike Jungmann, Georgios A Kaissis, et al.
Theranostics|March 15, 2019
A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic CancerAndreas W Berger, Daniel Schwerdel, Anke Reinacher-Schick, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2016
Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cellsIhsan Ekin Demir, Kristina Kujundzic, Paulo L Pfitzinger, et al.
Gut|January 21, 2015
A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signallingBo Kong, Weiwei Wu, Tao Cheng, et al.
Journal of Cachexia, Sarcopenia and Muscle|August 24, 2021
Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapyPauline Morigny, Doris Kaltenecker, Julia Zuber, et al.
Journal of Gastroenterology and Hepatology|May 28, 2026
Double EUS-Bypass Versus Conventional Endoscopic Strategies for Concurrent Malignant Gastric Outlet and Biliary ObstructionShanshan Shen, Shuang Nie, Jiaqi Shi, et al.
Pageof 77

Showing results (701-710 of 770) with videos related to

Sort By:
Pageof 77
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2017
Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment ResponseAlexander Muckenhuber, Anne Katrin Berger, Anna Melissa Schlitter, et al.
Journal of Cellular and Molecular Medicine|February 27, 2008
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profilingChristian Pilarsky, Ole Ammerpohl, Bence Sipos, et al.
Gastroenterology|January 3, 2021
mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote Kras<sup>G12D</sup>-Induced Acinar-to-Ductal Metaplasia and Early Pancreatic CarcinogenesisYamin Zhao, Benjamin Schoeps, Dianbo Yao, et al.
The Lancet. Gastroenterology & Hepatology|December 18, 2020
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trialVolker Kunzmann, Jens T Siveke, Hana Algül, et al.
EJNMMI Research|July 29, 2021
[<sup>18</sup>F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinomaFelix N Harder, Friederike Jungmann, Georgios A Kaissis, et al.
Theranostics|March 15, 2019
A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic CancerAndreas W Berger, Daniel Schwerdel, Anke Reinacher-Schick, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2016
Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cellsIhsan Ekin Demir, Kristina Kujundzic, Paulo L Pfitzinger, et al.
Gut|January 21, 2015
A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signallingBo Kong, Weiwei Wu, Tao Cheng, et al.
Journal of Cachexia, Sarcopenia and Muscle|August 24, 2021
Association of circulating PLA2G7 levels with cancer cachexia and assessment of darapladib as a therapyPauline Morigny, Doris Kaltenecker, Julia Zuber, et al.
Journal of Gastroenterology and Hepatology|May 28, 2026
Double EUS-Bypass Versus Conventional Endoscopic Strategies for Concurrent Malignant Gastric Outlet and Biliary ObstructionShanshan Shen, Shuang Nie, Jiaqi Shi, et al.
Pageof 77